Browse by Audience
Skip to content
Papers of the Week
Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache.
Abstract
Ubrogepant, a small-molecule calcitonin gene-related peptide receptor antagonist, was recently approved as an oral medication for the acute treatment of migraine. This study aimed to determine whether ubrogepant shows efficacy in a preclinical model of migraine-like pain and whether repeated oral administration of ubrogepant induces latent sensitization relevant to medication overuse headache in rats.